Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PHGE

BiomX Inc

Apr 17 • 04:00PM ET

0.2801

Dollar change -0.0002
Percentage change -0.07	%

Healthcare • Biotechnology • Israel • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.57	Insider Own	65.28%	Shs Outstand	45.98M	Perf Week	-17.98%
Market Cap	15.47M	Forward P/E	-	EPS next Y	-0.22	Insider Trans	-0.03%	Shs Float	19.17M	Perf Month	-22.19%
Income	-26.17M	PEG	-	EPS next Q	-0.07	Inst Own	0.64%	Short Float	1.14%	Perf Quarter	25.04%
Sales	0.00M	P/S	-	EPS this Y	50.98%	Inst Trans	-0.16%	Short Ratio	0.08	Perf Half Y	-6.63%
Book/sh	0.07	P/B	4.18	EPS next Y	12.00%	ROA	-39.47%	Short Interest	0.22M	Perf Year	-0.14%
Cash/sh	0.29	P/C	0.98	EPS next 5Y	-	ROE	-216.99%	52W Range	0.19 - 0.86	Perf YTD	0.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.31%	ROI	-223.25%	52W High	-67.24%	Beta	1.45
Dividend TTM	-	Quick Ratio	1.58	Sales past 5Y	0.00%	Gross Margin	-	52W Low	50.11%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	1.58	EPS Y/Y TTM	39.69%	Oper. Margin	0.00%	RSI (14)	40.72	Volatility	12.57% 12.08%
Employees	71	Debt/Eq	4.90	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.00
Option/Short	No / Yes	LT Debt/Eq	2.81	EPS Q/Q	39.21%	Payout	-	Rel Volume	0.05	Prev Close	0.28
Sales Surprise	-	EPS Surprise	45.45%	Sales Q/Q	-	Earnings	Apr 03 BMO	Avg Volume	2.61M	Price	0.28
SMA20	-21.08%	SMA50	-9.59%	SMA200	-16.27%	Trades		Volume	129,574	Change	-0.07%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-21	Initiated	Ladenburg Thalmann	Buy	$25

Apr-05-24 09:55AM	Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-04-24 07:49AM	BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure (GlobeNewswire) +8.57%
Apr-03-24 06:30AM	BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.90%
Mar-27-24 06:30AM	BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024 (GlobeNewswire) +6.07%
Mar-19-24 05:00AM	Telum Therapeutics appoints Dr. Subhendu Basu as CEO (PR Newswire)
06:30AM	Loading…
Mar-18-24 06:30AM	BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing (GlobeNewswire)
Mar-06-24 07:30AM	BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing (GlobeNewswire) +197.66%
Jan-04-24 08:00AM	BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-30-23 04:15PM	BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023 (GlobeNewswire) -13.67%
Nov-29-23 06:30AM	BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire) -46.43%
Nov-14-23 06:30AM	BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 08:00AM	BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference (GlobeNewswire)
Oct-18-23 08:00AM	BiomX Announces the Appointment of Edward L. Williams to its Board of Directors (GlobeNewswire)
Oct-04-23 06:34AM	BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Sep-07-23 09:00AM	BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023 (GlobeNewswire)
04:05PM	Loading…
Sep-06-23 04:05PM	BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 06:30AM	BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -9.29%
Aug-02-23 04:30PM	BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023 (GlobeNewswire)
Jun-08-23 05:00PM	NYSE American Initiates Delisting Proceedings for BiomX Warrants (GlobeNewswire)
May-31-23 03:00AM	BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC) (GlobeNewswire) +13.56%
May-15-23 06:30AM	BiomX Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.17%
May-12-23 08:00AM	BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors (GlobeNewswire) +9.97%
May-08-23 06:30AM	BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023 (GlobeNewswire)
May-05-23 06:30AM	BiomX Announces Second Closing of $7.5 Million Private Placement (GlobeNewswire) +7.18%
Mar-29-23 06:30AM	BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-27-23 07:00AM	BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023 (GlobeNewswire) +7.00%
Feb-22-23 06:35AM	BiomX Announces $7.5 Million Private Placement (GlobeNewswire)
06:30AM	BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-29-22 09:10AM	BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage (GlobeNewswire) +6.50%
Nov-09-22 06:30AM	BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
09:00AM	Loading…
Nov-02-22 09:00AM	BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022 (GlobeNewswire)
Sep-11-22 07:22AM	BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference (Business Wire)
Aug-10-22 06:30AM	BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire) -6.41%
Aug-07-22 03:17AM	BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022 (Business Wire)
Aug-04-22 11:20AM	BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease (Business Wire) +6.18%
Jul-06-22 01:45AM	BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange (Business Wire) -5.37%
Jun-28-22 06:30AM	Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers (Business Wire)
Jun-27-22 06:30AM	BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis (Business Wire)
May-24-22 01:52AM	BiomX Announces Corporate Restructuring (Business Wire) +8.74%
May-20-22 08:00AM	BiomX Announces Publication in the Journal, Bioinformatics (Business Wire)
May-11-22 06:30AM	BiomX Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire) -6.09%
May-06-22 07:00AM	BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients (Business Wire)
May-05-22 08:00AM	BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022 (Business Wire)
Mar-30-22 06:30AM	BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (Business Wire) +14.38%
Mar-23-22 08:00AM	BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022 (Business Wire)
Feb-24-22 08:00AM	BiomX Presenting at Three Upcoming Investor Conferences (Business Wire)
Jan-04-22 07:00AM	BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation (Business Wire)
Nov-17-21 08:00AM	BiomX Presenting at Two Upcoming Conferences in November (GlobeNewswire)
Nov-15-21 06:00AM	BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 08:00AM	BiomX to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 15, 2021 (GlobeNewswire)
Oct-25-21 10:00AM	Down 28.1% in 4 Weeks, Here's Why BiomX Inc. (PHGE) Looks Ripe for a Turnaround (Zacks)
Oct-18-21 07:00AM	BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study (GlobeNewswire) -12.35%
Oct-13-21 07:00AM	BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005 (GlobeNewswire) -5.15%
Sep-02-21 04:05PM	BiomX to Present at Upcoming September Investor Conferences (GlobeNewswire) -7.29%
Aug-16-21 06:30AM	BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) -7.65%
Aug-12-21 08:00AM	BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021 (GlobeNewswire)
Jul-26-21 08:13AM	BiomX Inc. Announces $15 Million Registered Direct Offering (GlobeNewswire) +9.45%
Jun-14-21 06:30AM	BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages (Business Wire)
Jun-09-21 06:30AM	BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference (Business Wire)
May-25-21 10:46AM	BiomX Reports Q1 Earnings; Shares Jump 6% (SmarterAnalyst)
May-24-21 06:30AM	BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates (Business Wire)
06:15AM	BiomX Inc to Host Earnings Call (ACCESSWIRE)
May-18-21 08:00AM	BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease (GlobeNewswire)
06:30AM	BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021 (Business Wire)
Apr-20-21 07:00AM	BiomX to Present at Upcoming April Investor Events (Business Wire)
Mar-31-21 06:30AM	BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update (Business Wire)
05:45AM	BiomX Inc to Host Earnings Call (ACCESSWIRE)
Mar-24-21 06:30AM	BiomX to Report Fourth Quarter and Full Year 2020 Financial Results on March 31, 2021 (Business Wire)
Mar-02-21 07:00AM	BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin (Business Wire) +10.77%
Mar-01-21 07:00AM	BiomX to Present at Upcoming March Investor Conferences (Business Wire) +7.29%
Feb-02-21 06:30AM	BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy (Business Wire)
Jan-04-21 06:30AM	BiomX to Present at Upcoming January Investor Conferences (Business Wire)
Dec-09-20 04:30PM	BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer (Business Wire)
Dec-02-20 06:21PM	Here is What Hedge Funds Think About BiomX Inc. (PHGE) (Insider Monkey) -5.06%
Nov-16-20 06:30AM	BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease (Business Wire)
Nov-12-20 06:30AM	BiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates (Business Wire)
06:15AM	BiomX Inc to Host Earnings Call (ACCESSWIRE)
Nov-10-20 04:30PM	BiomX to Present at Upcoming November Investor Conferences (Business Wire)
Nov-05-20 06:30AM	BiomX to Report Third Quarter 2020 Financial Results on Nov. 12, 2020 (Business Wire)
Nov-04-20 06:30AM	BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease (Business Wire)
Oct-21-20 06:30AM	BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the Infectious Disease Society of America (IDSA) IDWeek Conference 2020 (Business Wire)
Oct-05-20 06:30AM	BiomX Appoints Paul Sekhri and Alan Moses, M.D., to Board of Directors (Business Wire)
Sep-10-20 04:30PM	BiomX to Present at Upcoming September Investor Conferences (Business Wire)
Sep-02-20 06:30AM	BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease (Business Wire)
Aug-13-20 06:30AM	BiomX Reports Second Quarter 2020 Financial Results and Provides Business Update (Business Wire) -16.42%
Aug-12-20 12:17PM	Is BiomX Inc. (NYSEMKT:PHGE) Popular Amongst Institutions? (Simply Wall St.) -7.75%
Aug-06-20 07:00AM	BiomX to Report Second Quarter 2020 Financial Results on Aug. 13, 2020 (Business Wire)
May-14-20 06:30AM	BiomX Reports First Quarter 2020 Financial Results and Provides Business Update (Business Wire) -8.48%
May-11-20 05:00PM	BiomX to Announce First Quarter 2020 Financial Results on May 14, 2020 (Business Wire)
Apr-07-20 04:05PM	BiomX Announces Date of 2020 Annual Meeting of Stockholders (Business Wire) -11.28%
Mar-31-20 06:30AM	BiomX Announces Positive Topline Data from Phase 1 Study for Lead Candidate BX001 for Acne-Prone Skin (Business Wire) -9.33%
Mar-26-20 06:30AM	BiomX Reports Full Year 2019 Financial Results and Provides Business Update (Business Wire) +7.45%
Mar-20-20 08:00AM	BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting (Business Wire)
Feb-17-20 07:00AM	BiomX To Present Pre-clinical Data at the Plenary Session of the AACR Microbiome, Viruses, and Cancer Conference (Business Wire)
Dec-02-19 07:30AM	BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin (Business Wire)
Nov-12-19 07:30AM	BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis (Business Wire) -5.53%
07:25AM	Stone Street Group Initiates Coverage On BiomX Inc. (PR Newswire)
Nov-04-19 05:38PM	BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director (Business Wire)
07:30AM	BiomX To Present at Plenary Session of the AASLD Liver Conference (Business Wire)

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Oron Assaf	Chief Business Officer	Nov 29 '23	Sale	0.37	10,914	4,072	0	Dec 01 04:46 PM
Oron Assaf	Chief Business Officer	May 22 '23	Buy	0.27	3,192	872	10,914	May 24 06:03 AM
Oron Assaf	Chief Business Officer	May 19 '23	Buy	0.28	6,521	1,832	7,722	May 22 04:01 PM
Oron Assaf	Chief Business Officer	May 18 '23	Buy	0.27	1,201	328	1,201	May 22 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHGE

BiomX Inc

Upgrade your FINVIZ experience